Report
Julien Onillon
EUR 250.00 For Business Accounts Only

Eurobio Scientific: Estimates and target price revised upwards

The small French distributor of in-vitro specialty diagnostics published an 18% increase in its half-yearly sales. This increase, which must be compared to the 11% increase in sales in the second half of 2018 and 2% in the previous half, is well above our expectations. It is also well above Eurobio's long-term objectives. As a reminder, the company has set itself the objective of increasing its sales by nearly 8% per year and reaching EUR 60 million in revenue (excluding acquisitions) by 2020.

Underlying
Eurobio-Scientific SA

Eurobio Scientific SA, formerly Diaxonhit, is a France-based biotechnology company engaged in the field of in-vitro diagnostic. It is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The Company owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. It consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. It has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. It operates through Genbio and Eurobio Capforce Plus.

Provider
LPE Research
LPE Research

LPE Research is a new independent equity research firm offering research on demand to fund managers. 

We believe our independent equity research on demand model dedicated to fund managers is the future, that our disruptive equity research on demand model will save money and addresses fund managers real needs, that fund managers should pay only for the equity research they need and if it creates value for them. And we ambition to become fund managers primary outperformance partner.

Our equity research services on demande services are:
- Stock conviction: independent reports
- Stock checking: on demand financial analysis
- Stock coverage: alert and coverage of specific companies
- Stock ideas (to come): list of investment opportunities

Analysts
Julien Onillon

Other Reports on these Companies
Other Reports from LPE Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch